ongoing

More documents

Recommendations

Info

Action: For adoption 5.1.6. Stivarga - regorafenib - EMEA/H/C/002573/II/0020 Bayer Pharma AG Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus Scope: “Extension of indication of Stivarga to include treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with one systemic therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the EU SmPC are updated. The package leaflet and RMP (version 5.0) have been updated accordingly. Furthermore, the PI is brought in line with the latest QRD template version 10.0.” Action: For adoption 5.1.7. Tasigna - nilotinib - Orphan - EMEA/H/C/000798/II/0084/G Novartis Europharm Ltd Rapporteur: Sinan B. Sarac, Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Doris Stenver Scope: “This grouped variation application consists of three Type II variation applications as follows: - Update of the 150 mg SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1, and Package Leaflet based on the results from study CAMN107I2201 (ENESTfreedom): A Phase II, single-arm study evaluating nilotinib treatment discontinuation (treatment-free remission (TFR)) in newly-diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) who achieved a sustained deep molecular response. - Update of the 150 mg and 200 mg Tasigna SmPC sections 4.1, 4.2, 4.4, 4.8 and 5.1, and Package Leaflet based on the results from study CAMN107A2408 (ENESTop): A Phase II, single-arm study evaluating nilotinib treatment discontinuation (treatment-free remission (TFR)) in patients with Ph+ CML-CP who achieved a sustained deep molecular response on nilotinib treatment after switching from imatinib treatment. - Update of the 200 mg Tasigna SmPC sections 4.8 and 5.1, based on the results from study CAMN107A2405 (ENESTcmr): A Phase III open-label, randomised study to evaluate nilotinib or imatinib treatment in patients with Ph+ CML-CP who have not achieved a deep molecular response after previous imatinib therapy. Additional changes to the labelling are proposed to comply with the latest QRD template version 10. An updated RMP, version 16, is also provided in this application.” Action: For adoption Request for Supplementary Information adopted on 13.10.2016. 5.1.8. Truvada - emtricitabine / tenofovir disoproxil - EMEA/H/C/000594/II/0131 Gilead Sciences International Ltd Committee for medicinal products for human use (CHMP) EMA/CHMP/117089/2017 Page 22/39
Rapporteur: Greg Markey, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Julie Williams Scope: “Extension of Indication to include treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years for Truvada. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the Risk Management plan (v.13) are updated in accordance.” Action: For adoption Request for Supplementary Information adopted on 10.11.2016. 5.1.9. Victoza - liraglutide - EMEA/H/C/001026/II/0042 Novo Nordisk A/S Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Menno van der Elst Scope: “Extension of Indication to include a new indication/population in Section 4.1 of the SmPC for Victoza. As a consequence, sections 4.2, 4.4, 4.7, 4.8, 5.1 and 6.5 of the SmPC are updated to add warnings and update the safety information based on the findings of the LEADER (EX2211- 3748) clinical study results, which constitutes the data set for the application. The Package Leaflet and Labelling (sections 17 and 18) are updated in accordance. Updates to the liraglutide RMP based on the LEADER study results are also proposed: RMP Version 27 was submitted with the application, showing the proposed RMP changes.” Action: For adoption 5.1.10. Mekinist Tafinlar – trametinib dabrafenib - EMEA/H/C/WS0996 Novartis Europharm Ltd Lead Rapporteur: Filip Josephson, Lead Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Ulla Wändel Liminga Scope: “Extension of indication to include the combination treatment with trametinib and dabrafenib of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the Mekinist and Tafinlar SmPC are updated. The Package Leaflet and RMP are updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to align the SmPCs of Mekinist and Tafinlar. Furthermore, the Product Information is brought in line with the latest QRD template version 10.” Action: For adoption Request for Supplementary Information adopted on 10.11.2016. Committee for medicinal products for human use (CHMP) EMA/CHMP/117089/2017 Page 23/39
Page 1 and 2: 20 February 2017 EMA/CHMP/117089/20
Page 3 and 4: 3.2.11. - sarilumab - EMEA/H/C/0042
Page 5 and 6: 8.2.2. Recommendation for PRIME eli
Page 7 and 8: 14.3.12. Safety Working Party (SWP)
Page 9 and 10: 2.1.3. - pentosan polysulfate sodiu
Page 11 and 12: Scope: Opinion Action: For adoption
Page 13 and 14: 3.2.9. - febuxostat - EMEA/H/C/0043
Page 15 and 16: Scope: Day 120 list of questions Ac
Page 17 and 18: List of Questions adopted on 13.10.
Page 19 and 20: 4.3. Extension of marketing authori
Page 21: accordance. In addition, the Market
Page 25 and 26: these contain commercially confiden
Page 27 and 28: An increased risk has not been seen
Page 29 and 30: 10.6. Community Interests - Referra
Page 31 and 32: 13.2. Innovation Task Force briefin
Page 33 and 34: 14.2.3. Committee for Herbal Medici
Page 35 and 36: 14.3.8. Rheumatology/Immunology Wor
Page 37 and 38: 16. Explanatory notes The notes bel
Page 39 and 40: particular medicine or class of med
Page 41 and 42: B.6.7. Type II Variations scope of
Page 43 and 44: MAH: Baxalta Innovations GmbH, Rapp
Page 45 and 46: MAH: Janssen-Cilag International NV
Page 47 and 48: amino acids and vitamins, acts as a
Page 49 and 50: EMEA/H/C/004137/II/0001 MAH: Zentiv
Page 51 and 52: MAH: Pfizer Limited, Rapporteur: Kr
Page 53 and 54: on 16.02.2017. BeneFIX - nonacog al
Page 55 and 56: local representatives in the Packag
Page 57 and 58: evise the instructions for handling
Page 59 and 60: subcutaneous doses of alirocumab on
Page 61 and 62: adverse drug reaction (hepatic enzy
Page 63 and 64: ALT due to treatment with the HCV c
Page 65 and 66: the implementation of the use of co
Page 67 and 68: Epclusa - sofosbuvir / velpatasvir
Page 69 and 70: Imbruvica - ibrutinib - EMEA/H/C/00
Page 71 and 72: TRYPHAENA study( BO22280) A randomi
Page 73 and 74:
SmPC under the sub-heading 'Tabulat
Page 75 and 76:
on 26.01.2017. Zykadia - ceritinib
Page 77 and 78:
important identified risk.” Reque
Page 79 and 80:
term Safety of Infliximab Study C01
Page 81 and 82:
MAH: Amgen Europe B.V., Rapporteur:
Page 83 and 84:
Rapporteur: Hanne Lomholt Larsen WS
Page 85 and 86:
EMEA/H/C/003825/WS1119/0007/G MAH:
Page 87 and 88:
Constella - linaclotide - EMEA/H/C/
Page 89 and 90:
The Package Leaflet and Risk Manage
Page 91 and 92:
B.6.8. CHMP assessed procedures sco
Page 93 and 94:
B.6.9. CHMP assessed procedures sco
Page 95 and 96:
Weight and Cardiovascular Risk Fact
Page 97 and 98:
Rapporteur: Hanne Lomholt Larsen, P
Page 99 and 100:
EMEA/H/C/004156/WS1133/0011/G Strib
Page 101 and 102:
in a type II variation (Procedure N
Page 103 and 104:
Exelon, Lead Rapporteur: Alexandre
Page 105:
G.3.1. List of procedures concludin
show all

ongoing

Create successful ePaper yourself

Delete template?

Save as template?